191 related articles for article (PubMed ID: 9145869)
1. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor.
Poppe SM; Slade DE; Chong KT; Hinshaw RR; Pagano PJ; Markowitz M; Ho DD; Mo H; Gorman RR; Dueweke TJ; Thaisrivongs S; Tarpley WG
Antimicrob Agents Chemother; 1997 May; 41(5):1058-63. PubMed ID: 9145869
[TBL] [Abstract][Full Text] [Related]
2. In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates.
Chong KT; Pagano PJ
Antimicrob Agents Chemother; 1997 Nov; 41(11):2367-73. PubMed ID: 9371335
[TBL] [Abstract][Full Text] [Related]
3. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha.
Pagano PJ; Chong KT
J Infect Dis; 1995 Jan; 171(1):61-7. PubMed ID: 7528253
[TBL] [Abstract][Full Text] [Related]
4. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class.
Turner SR; Strohbach JW; Tommasi RA; Aristoff PA; Johnson PD; Skulnick HI; Dolak LA; Seest EP; Tomich PK; Bohanon MJ; Horng MM; Lynn JC; Chong KT; Hinshaw RR; Watenpaugh KD; Janakiraman MN; Thaisrivongs S
J Med Chem; 1998 Aug; 41(18):3467-76. PubMed ID: 9719600
[TBL] [Abstract][Full Text] [Related]
5. Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease.
Lamarre D; Croteau G; Wardrop E; Bourgon L; Thibeault D; Clouette C; Vaillancourt M; Cohen E; Pargellis C; Yoakim C; Anderson PC
Antimicrob Agents Chemother; 1997 May; 41(5):965-71. PubMed ID: 9145853
[TBL] [Abstract][Full Text] [Related]
6. Anti-human immunodeficiency virus type 1 activities of U-90152 and U-75875 in human brain cell cultures.
Peterson PK; Gekker G; Hu S; Chao CC
Antimicrob Agents Chemother; 1994 Oct; 38(10):2465-8. PubMed ID: 7530933
[TBL] [Abstract][Full Text] [Related]
7. Anti-human immunodeficiency virus type 1 activities of novel non-nucleoside reverse transcriptase inhibitors.
Nottet HS; Oteman MH; Visser MR; Verhoef J
J Antimicrob Chemother; 1994 Feb; 33(2):366-8. PubMed ID: 7514164
[No Abstract] [Full Text] [Related]
8. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease.
Patick AK; Mo H; Markowitz M; Appelt K; Wu B; Musick L; Kalish V; Kaldor S; Reich S; Ho D; Webber S
Antimicrob Agents Chemother; 1996 Feb; 40(2):292-7. PubMed ID: 8834868
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells.
Okamoto M; Okamoto T; Baba M
Antimicrob Agents Chemother; 1999 Mar; 43(3):492-7. PubMed ID: 10049256
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine.
Chong KT; Pagano PJ
Antiviral Res; 1997 Mar; 34(1):51-63. PubMed ID: 9107385
[TBL] [Abstract][Full Text] [Related]
11. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
Chong KT; Pagano PJ; Hinshaw RR
Antimicrob Agents Chemother; 1994 Feb; 38(2):288-93. PubMed ID: 7514857
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.
Rusconi S; La Seta Catamancio S; Citterio P; Kurtagic S; Violin M; Balotta C; Moroni M; Galli M; d'Arminio-Monforte A
Antimicrob Agents Chemother; 2000 May; 44(5):1328-32. PubMed ID: 10770770
[TBL] [Abstract][Full Text] [Related]
13. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.
Norelli S; El Daker S; D'Ostilio D; Mele F; Mancini F; Taglia F; Ruggieri A; Ciccozzi M; Cauda R; Ciervo A; Barreca ML; Pistello M; Bendinelli M; Savarino A
Curr HIV Res; 2008 Jun; 6(4):306-17. PubMed ID: 18691029
[TBL] [Abstract][Full Text] [Related]
14. Equilibrium distribution of HIV antiviral drugs into human peripheral blood mononuclear cells (PBMC) is controlled by free drug concentration in the extracellular medium.
Koeplinger KA; Raub TJ; Padbury GE; Zhao Z
J Pharm Biomed Anal; 1999 Mar; 19(3-4):399-411. PubMed ID: 10704105
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
16. L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350).
Robinson WE
Antiviral Res; 1998 Aug; 39(2):101-11. PubMed ID: 9806487
[TBL] [Abstract][Full Text] [Related]
17. Tipranavir: PNU 140690, tipranivir.
Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
Campbell TB; Young RK; Eron JJ; D'Aquila RT; Tarpley WG; Kuritzkes DR
J Infect Dis; 1993 Aug; 168(2):318-26. PubMed ID: 7687641
[TBL] [Abstract][Full Text] [Related]
19. In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol.
St Clair MH; Pennington KN; Rooney J; Barry DW
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S83-91. PubMed ID: 7552518
[TBL] [Abstract][Full Text] [Related]
20. Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors.
Shafer RW; Winters MA; Iversen AK; Merigan TC
Antimicrob Agents Chemother; 1996 Dec; 40(12):2887-90. PubMed ID: 9124861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
